Literature DB >> 6445274

Pharmacokinetics of zimelidine. Systemic availability of zimelidine and norzimelidine in human volunteers.

D Brown, D H Scott, D B Scott, M Meyer, D Westerlund, J Lundström.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6445274     DOI： 10.1007/bf00562618

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

1.  THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN.

Authors:  S E Bradley; F J Ingelfinger; G P Bradley; J J Curry
Journal:  J Clin Invest       Date:  1945-11       Impact factor: 14.808

2.  (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake.

Authors:  S B Ross; S O Ogren; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-08

3.  Influence of first-pass effect on availability of drugs on oral administration.

Authors:  M Gibaldi; R N Boyes; S Feldman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

4.  Zimelidine: a therapeutic and pharmacokinetic study in depression.

Authors:  A Coppen; V A Ramo Rao; C Swade; K Wood
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

5.  Tricyclic antidepressant agents. II. Effect of oral administration on the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices of the midbrain-hypothalamus region of the rat.

Authors:  S B Ross; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

6.  Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain.

Authors:  S B Ross; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

7.  Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z)- and (E)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues.

Authors:  S B Ross; A L Renyi
Journal:  Neuropharmacology       Date:  1977-01       Impact factor: 5.250

8.  Biochemical effects of zimelidine in man.

Authors:  L Bertilsson; J R Tuck; B Siwers
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953
  8 in total
  7 in total

1.  Effects of zimelidine on serotoninergic and noradrenergic neurons after repeated administration in the rat.

Authors:  S B Ross; H Hall; A L Renyi; D Westerlund
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

2.  Possible hepatotoxicity of zimelidine.

Authors:  G K Simpson; N M Davidson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-22

3.  Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo.

Authors:  S B Ross; B Aperia; J Beck-Friis; S Jansa; L Wetterberg; A Aberg
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

4.  Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine.

Authors:  B L Love; R G Moore; J Thomas; S Chaturvedi
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Influence of renal failure on the kinetics of zimeldine and norzimelidine.

Authors:  N Ferry; G Cuisinaud; P Cochat; N Pozet; P Y Zech; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Pharmacokinetic study of zimelidine using a new GLC method.

Authors:  G Caillé; E Kouassi; C de Montigny
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 7.  Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R C Heel; P A Morley; R N Brogden; A A Carmine; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.